



Cancer Research Cluster
to Facilitate and Structure
Oncology Research

CANCÉROPÔLE LYON AUVERGNE RHÔNE-ALPES




Missions of the Cancer Research Cluster CLARA

To facilitate synergy to improve
Cancer Research output for
Patients

CLARA's mission is to facilitate Cancer Research in the Rhône-Alpes Auvergne inter-region by combining academic, clinical and industrial strengths around innovative and high-potential projects with a double objective:

- to accelerate transfer of findings to Patients
- to perform economic development of Oncology Research




Why a Cancer Research Cluster in Rhône-Alpes Auvergne?

When national strategy meets regional dynamics

The Cancer Research Cluster CLARA was created in 2003, as the result of a national mobilization against Cancer* and on a tradition in the region to invest in Cancer Research and Public/Private Partnerships.


As a reference entity in French Oncology Research, the Cancer Research Cluster CLARA is an actor of the national and inter-regional strategy's implementation.



*Cancer Plans I (2003-2007) and II (2009-2013) coordinated by the French National Cancer Institute (INCa)

Who are CLARA's Major Partners?

CLARA is involved with numerous partners:



A Dynamic and Renowned Oncology Research Network

CLARA leads a dynamic network based on:


- 250 cutting-edge academic and clinical teams and 19 industrial partners in the pharmaceutical and biotechno-logical sections associated within 160 projects R&D projects
- Five IBiSA labeled* platforms
- Three IBiSA labeled* biological resource centers
- Three early clinical trial centers certified by INCa

*IBiSA: National label "Infrastructures in Biology, Health and Agronomy"



How does CLARA Intervene?

Six thematic axes covering an extensive range within Cancer Research




Innovative Tools and Inspiring Know-How

Development of the “Proof of Concept” program: technological transfer and clinical development of Oncology Research

The original “Proof of Concept” program, as developed by CLARA in 2005, finances a key step: industrial and clinical transfer of Research findings.

Partnerships are developed between academic, clinical and industrial actors through high-potential projects to promote therapeutic, diagnostic and technological innovations.

In 2011, 25 “Proof of Concept” projects are financed (total budget €32M) including six successful projects in development.



How to Define CLARA's Actions?



Our actions*

- Elaborating, supporting and financing original R&D projects
- Reinforcing high-level international projects
- Initiating and developing new collaborations by identifying appropriate partners
- Accentuating networking with high-impact scientific events

Our commitments

- Promotion of scientific excellence
- Development of multidisciplinary Oncology Research and Public/Private Partnerships
- Commitment to innovation and marketable applications
- Continuous concern over the benefit for Patients

*Non exhaustive list

International Influence

To reinforce the visibility and attractiveness of inter-regional Oncology Research, CLARA is engaged in high-impact international actions:

- **Launching of ambitious projects with high international impact:** European Lymphoma Institute, World Sarcoma Network, European Center for Nutrition and Health...
- **Participation in international programs:** International Cancer Genome Consortium (ICGC), 22 European projects...
- **Collaborations with renowned international Research organizations:** International Agency for Research on Cancer (IARC), German Cancer Research Center in Heidelberg (DKFZ), Institute for Bioengineering of Catalonia (IBEC), Polytechnic Federal School of Lausanne (EPFL), Swiss Institute for Experimental Cancer Research (ISREC), Weizmann Institute (Israel)...
- **Extension of the CLARA "Proof of Concept" program to other European countries**
- **Development of collaborations with China**



Which Results*?



→ 160 ongoing projects

→ Clinical Research projects

- A mini-robot for laparoscopic surgery on the European and American markets (Prostate Cancer...)
- A high-intensity focused ultra-sound device for metastatic liver Cancer in phase II clinical development
- A radio-immunotherapy candidate in early clinical development (Sarcoma)
- An immunomonitoring platform for chemotherapy (Breast Cancer)

→ Nanomedicine Research projects
(Pre-clinical stage)

- Hybrid imaging nanoprobes for cellular therapy follow-up (Melanoma)
- Cellular and proteomic sampling tool for tumoral nodes
- Photosensitive nanoparticles (Glioblastoma)

→ Contribution to the creation of six companies including the setting up of a Japanese company branch in Lyon

→ A budget of €150M



infos@canceropole-clara.com • www.canceropole-clara.com

60, avenue Rockefeller • 69008 Lyon • France • Tel. +33 (0)4 37 90 17 10 • Fax +33 (0)4 37 90 27 03



Fondation reconnue d'utilité publique

Under the aegis of the Léa and Napoléon Bullukian Foundation